New hope for leprosy patients: experimental drug targets painful skin flares
NCT ID NCT07172659
First seen Oct 31, 2025 · Last updated May 16, 2026 · Updated 30 times
Summary
This study tests an experimental drug called dovramilast for people with moderate to severe leprosy type 2 reaction, a painful skin condition. About 45 adults will receive either 100 mg or 150 mg of dovramilast or standard treatments for 12 weeks. The goal is to see if the new drug can reduce skin lesions and improve fever safely.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ERYTHEMA NODOSUM LEPROSUM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre de Dépistage de Traitement de la Lèpre et de l'Ulcère de Burulli
Abomey-Calavi, Benin
-
Chr de Divo
Divo, Côte d’Ivoire
-
Harborview Medical Center, University of Washington
Seattle, Washington, 98104, United States
-
Philippine General Hospital, University of the Philippines, Manila
Manila, Philippines
-
Universitas Gadjah Mada
Yogyakarta, Indonesia
-
University of Southern California
Los Angeles, California, 90007, United States
Conditions
Explore the condition pages connected to this study.